New drug zilucoplan shows promise for muscle weakness in myasthenia gravis patients

NCT ID NCT06815133

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how well a new drug called Zilucoplan works for people with myasthenia gravis, a disease that causes muscle weakness. Researchers will track 55 French patients over three months to see if the drug improves muscle strength and daily life, and check for side effects. The goal is to find a better treatment option for this challenging condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU NICE

    RECRUITING

    Nice, Alpes Maritimes, 06000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.